Jazz Buys Rare Epilepsy Drug Company for Up to $1.32 Billion
Jazz Pharmaceuticals acquires Actio Biosciences for up to $1.32 billion, adding experimental drug ABS-1230 for rare KCNT1 epilepsy with no approved treatments.
/ 7 items
#JAZZ↓
Benchmark Upgrades AbCellera to Buy with $11 Target on Major Jazz Pharmaceuticals Partnership
AbCellera gets a boost after Jazz deal brings upfront cash and future growth potential through cancer antibody programs and milestones.
Jazz Pharmaceuticals Strikes Major Collaboration with AbCellera for Next-Generation Multispecific Antibodies
Jazz Pharmaceuticals and AbCellera enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors.
Ziihera GEA Trial: Modest Gains Come With Severe Side Effects
Jazz new stomach cancer drug extends survival by 7 months but causes severe side effects in 25% of patients. Ziihera-only combination failed to achieve statistical significance for overall survival at first analysis.
Zymeworks & Jazz Pharmaceuticals Stocks Surge on Positive Cancer Trial Results
Zymeworks jumps 31% and Jazz Pharmaceuticals rises 26% after announcing successful Phase 3 trial results for Ziihera cancer treatment targeting stomach and esophageal cancers.
U.S. FDA Approves Jazz's Combination Therapy for Lung Cancer
The FDA approved the Zepzelca/Tecentriq drug combo as a maintenance treatment for advanced small cell lung cancer.